Alto Neuroscience, Inc. ANRO
Alto Neuroscience, Inc. (NYSE: ANRO) is a CNS/neurology/psychiatry drug developer. Its lead program, ALTO-207, is in Phase 2 for Treatment-resistant depression. Its next catalyst on record is ALTO-300: Phase 2b topline data (H1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: ALTO-300 — Phase 2b topline data (H1 2027). 5 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ALTO-207 | TRD | small molecule | Phase 2b topline 2027-H2; adjunctive Phase 3 start by early 2027 |
| ALTO-300 | MDD (EEG biomarker) | small molecule | Phase 2b topline 2027-H1 |
| ALTO-100 | Bipolar depression | small molecule | Phase 2b topline mid-2027 |
| ALTO-101 | Cognitive impairment associated with schizophrenia | small molecule | Phase 2 POC missed primary endpoints (Apr 2026); evaluating next steps |
| ALTO-203 | MDD with anhedonia | small molecule | Indication under evaluation |
| ALTO-208 | Parkinson's disease | small molecule | — |
| ALTO-202 | MDD | small molecule | Planning next phase |
Recent results and decisions
- May 13, 2026started Randomized, placebo-controlled Phase 2b of ALTO-207 in ~178 TRD adults initiated in April 2026.
In April 2026, Alto initiated a randomized, double-blind, placebo-controlled Phase 2b trial of ALTO-207 as an adjunctive treatment in approximately 178 adults with TRD
Filing - Apr 1, 2026missed ALTO-101 missed primary EEG and cognitive endpoints vs placebo; theta-ITC d=0.34, p=0.052 (n=83); company will not advance independently in CIAS.
ALTO-101 did not achieve statistical significance on primary electroencephalography (EEG) or cognitive endpoints versus placebo; however, the study demonstrated directional improvements across certain EEG measures, including a near-significant effect on theta-ITC (n=83, d=0.34, p=0.052)
Filing - Apr 1, 2026discontinued Company will not independently advance ALTO-101 in CIAS and will seek partners, prioritizing ALTO-207.
Based on these results, the Company does not plan to independently advance ALTO-101 in CIAS and will instead prioritize resources toward its lead program, ALTO-207
Filing
1 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.